Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women

Oncology

Volumn 69, Issue 1, 2005, Pages 1-9

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Anastrozole; Aromatase inhibitors; Early breast cancer; Efficacy; Safety

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TAMOXIFEN; TOREMIFENE;

ARTHRALGIA; ARTHRITIS; BONE ATROPHY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; EMBOLISM; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FLUID RETENTION; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HIP FRACTURE; HOSPITALIZATION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LETHARGY; LONG TERM CARE; LUNG EMBOLISM; MENSTRUAL IRREGULARITY; META ANALYSIS; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SPINE FRACTURE; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; WRIST FRACTURE;

EID: 23944482923     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer 1984;53(suppl):630-643.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
3. Litherland S, Jackson IM: Antiestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988;15:183-194.
4. Bissett D, Davis JA, George WD: Gynaecological monitoring during tamoxifen therapy. Lancet 1994;344:1244.
5. Cutuli B, Petit JC, Fricker JP, Schumacher C, Veten M, Abecassis J: Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: Occurrence of thromboembolic complications. Oncol Rep 1994;1:63.
6. Meier CR, Jick H: Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45:608-612.
7. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieland S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
8. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T: First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360:817-824.
9. ACOG Committee Opinion: Number 232. Obstet Gynecol 2000;95:1C-3C.
10. Fisher B, Dignam J, Bryant J, Wolmark N: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
11. National Comprehensive Cancer Network: Breast Cancer. Clinical Practice Guidelines in Oncology - v.1.2004: www.nccn.org/physician_gls/f_guidelines.html. Accessed 22 June 2004.
12. Brodie AM, Njar VC: Aromatase inhibitors and breast cancer. Semin Oncol 1996;23:10-20.
13. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
14. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
15. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone on in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
16. Duffy SR, Greenwood M: The endometrial cancer data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial indicates a protective effect of anastrozole (Arimidex) upon the endometrium (abstract). Breast Cancer Res Treat 2003;82(suppl 1):S29.
17. Locker GY, Eastell R: The time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen. Alone or in Combination) trial (abstract). Proc Am Soc Clin Oncol 2003;22: 25.
18. Writing Group for the Women's Health Initiative (WHI) Investigators: Risks and benefits of estrogen and progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized trial. J Am Med Assoc 2002;288:321-333.
19. Sainsbury R, Howell A: Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial (abstract). Breast Cancer Res Treat 2003;82(suppl 1):S27.
20. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, Franchi R, Failla G, Bordonaro R, Sismondi P: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment (abstract). Breast Cancer Res Treat 2003;82(suppl 1):S6-S7.
21. Jakesz R, Kaufmann M, Gnant M, Jonat W, Mittleboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Samonigg H: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial (abstract). Breast Cancer Res Treat 2004;88(suppl 1):S7.
22. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 post-menopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-3757.
23. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-2258.
24. Nabholtz TM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
25. Goss PE, Ingle TN, Martino S, Robert NT, Muss HB, Piccart MT, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams TS, Therasse P, Palmer MT, Pater TL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
26. Goss PE, Ingle JN, Martino S, Robert NT, Muss HB, Piccart MT, Castiglione MM, Tu D, Shepherd LE, Pater JL: Updated analysis of the NCIC CTG MA17 randomized placebo (P) controlled trial of letrozole (L) after 5 years of tamoxifen in postmenopausal women with early stage breast cancer (abstract). Proc Am Soc Clin Oncol 2004;23:87.
27. 7 Coombes RC, Hall E, Gibson LT, Paridaens R, Tassem T, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss TM: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
28. Lønning PE, Geisler T, Krag LE, Ottestad L, Bremnes Y, Hagen AI, Schlichting E, Polli A, Paolini T, Massimini G: Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk (abstract). Proc Am Soc Clin Oncol 2004;23:6.
29. Winer EP, Hudis C, Burstein H, Byant J, Chlebowski RT, Ingle TN, Edge SB, Mamounas EP, Gelber R, Gralow T, Goldstein LJ, Pritchard KI, Braun S, Cobleigh M, Langer AS, Perotti T, Powles TJ Whelan TJ, Browman GP: American Society of Clinical Oncology Technology Group Update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21:2597-2599.
30. Wirz B, Valles B, Parkinson A, Madan A, Probst A, Zimmerlin A, Gut J: CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (Femara). ISSX Proc 1996; 10:359.
31. Grimm SW, Dyroff MC: Inhibition of human drag metabolizing cytochrome P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 1997;25:598-602.
32. Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffranchi A: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995;72:1007-1012.
33. Kataja V, Hietanen P, Joensuu H, Ala-Luhtala T, Asola R, Kokko R, Korhonen T, Holli K: The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - A randomised study (abstract). Breast Cancer Res Treat 2002;76(suppl 1):S156.
34. Sawada S, Sato K: Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer (abstract). Breast Cancer Res Treat 2003;82(suppl 1):S31-S32.
35. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA: Effect of letrozole on the lipid profile in post-menopausal women with breast cancer. Eur J Cancer 2001;37:1510-1513.
36. Lohrisch C, Paridaens R, Dirix LY, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Yague C, Duchateau L, Lobelle JP, Piccart M: No adverse impact on serum lipids of the irreversible aromatase inactivator, Aromasin [exemestane (E)] in 1st-line treatment of metastatic breast cancer (MBC): Companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia Upjohn (abstract). Proc Am Soc Clin Oncol 2001;20:43a.
37. Engan T, Krane J, Johannessen DC, Lønning PE, Kvinnsland S: Plasma changes in breast cancer patients during endocrine therapy - Lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995;36:287-297.
38. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR: Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239-2243.
39. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 2000;15:1526-1536.
40. Chapurlat RD, Bauer DC, Cummings SR: Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: Study of osteoporotic fractures. Bone 2001;29:381-387.
41. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R: Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-4475.
42. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B: Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733-738.
43. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD: Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: The EPIDOS study. J Bone Miner Res 2000;15:1835-1841.
44. Eastell R, Adams J: Results of the 'Arimidex' (anastrozole, A), Tamoxifen (T), Alone or in Combination (C) (ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC Trialists' Group) (abstract). Ann Oncol 2002;13(suppl 5):32.
45. Eastell R: Effect of anastrozole of bone mineral density: 2 year results of the Arimidex (anastrozole) Tamoxifen, Alone or in combination (ATAC) trial. Poster presented at the 25th American Society for Bone and Mineral Research Annual Meeting, 19-23 September 2003, Minneapolis, USA.
46. Coleman R: Effect of anastrozole on bone mineral density and bone fractures: Results from the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial (abstract). Oral presentation at the 4th European Breast Cancer Conference, 16-20 March 2004, Hamburg, Germany. Ann Oncol 2004;15(suppl 3):11, 64.
47. Heshmati HM, Khosla S, Robins SP, O'Fallon MW, Melton JL, Riggs BL: Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172-178.
48. Wojtacki J, Zielinski KW, Wiraszka R, Nowaczyk M, Hajdukiewicz W, Lesniewski-Kmak K, Lamentowicz K, Piotrowska M: Letrozole reduces bone mass in breast cancer patients as measured by digital radiometry of clavicle and rib (abstract). Breast Cancer Res Treat 2003;82(suppl 1):S107.
49. Goss P: Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002;9(suppl):2-8.
50. Ferrari L, Bajetta E, Martinetti A, Celio L, Longarini R, La Torre I, Buzzoni R, Gattinoni L, Seregni E, Bombardieri E: Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol 2003;22:1081-1089.
51. Mortimer JE, Urban JH: Long-term toxicities of selective estrogen-receptor modulator antiaromatase agents. Oncology 2003;17:652-659.
52. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(suppl):S1-S34.
53. Goss PE, Thomsen T, Banke-Bochita J, Hadji P: Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover and lipid metabolism in healthy volunteers (abstract). Breast Cancer Res Treat 2003;82(suppl 1):S101.
54. Evans TR, di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, Coombes RC: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933-5939.
55. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994;30:103-111.
56. Wolter J, Robert J, Harvey N, Berkowitz I, Plourde PV: Arimidex (ZD1033): A phase I study of a new, selective orally active aromatase inhibitor in postmenopausal women with advanced breast cancer (abstract). Proc Am Soc Clin Oncol 1995;14.
57. Bisagni G, Cocconi G, Scaglione F, Fraschini F, Poster C, Trunet PF: Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996;7:99-102.
58. Bajetta E, Zilembo N, Dowsett M, Guillevin L, Di Leo A, Celio L, Martinetti A, Marchiano A, Pozzi P, Stani S, Bichisao E: Double blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999;35:208-213.
59. Bajetta E, Zilembo N, Noberasco C, Martinetti A, Mariani L, Ferrari L, Buzzoni R, Greco M, Bartoli C, Spagnoli I, Danesini GM, Artale S, Paolini J: The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer 1997;33:587-591.
60. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L: Multicenter, phase II trial of exemestane as third-line hormonal therapy of post-menopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 1999;17:3418-3425.
61. Michaud LB, Buzdar AU: Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 1999;21:297-309.
62. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.